Abstract | BACKGROUND AND PURPOSE: METHODS: RESULTS: During 1.94 years (median) of follow-up, 172 patients (1.2%) experienced 175 ICH events at a rate of 0.67% per year. The significant, independent predictors of ICH were race (Asian: hazard ratio, 2.02; 95% CI, 1.39-2.94; black: hazard ratio, 3.25; 95% CI, 1.43-7.41), age (1.35; 1.13-1.63 per 10-year increase), reduced serum albumin (1.39; 1.12-1.73 per 0.5 g/dL decrease), reduced platelet count below 210×10(9)/L (1.08; 1.02-1.13 per 10×10(9)/L decrease), previous stroke or transient ischemic attack (1.42; 1.02-1.96), and increased diastolic blood pressure (1.17; 1.01-1.36 per 10 mm Hg increase). Predictors of a reduced risk of ICH were randomization to rivaroxaban (0.60; 0.44-0.82) and history of congestive heart failure (0.65; 0.47-0.89). The ability of the model to discriminate individuals with and without ICH was good (C-index, 0.69; 95% CI, 0.64-0.73). CONCLUSIONS:
|
Authors | Graeme J Hankey, Susanna R Stevens, Jonathan P Piccini, Yuliya Lokhnygina, Kenneth W Mahaffey, Jonathan L Halperin, Manesh R Patel, Günter Breithardt, Daniel E Singer, Richard C Becker, Scott D Berkowitz, John F Paolini, Christopher C Nessel, Werner Hacke, Keith A A Fox, Robert M Califf, ROCKET AF Steering Committee and Investigators |
Journal | Stroke
(Stroke)
Vol. 45
Issue 5
Pg. 1304-12
(May 2014)
ISSN: 1524-4628 [Electronic] United States |
PMID | 24743444
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Morpholines
- Thiophenes
- Vitamin K
- Warfarin
- Rivaroxaban
|
Topics |
- Aged
- Anticoagulants
(administration & dosage, adverse effects)
- Asian People
(ethnology)
- Atrial Fibrillation
(blood, drug therapy, epidemiology)
- Black People
(ethnology)
- Double-Blind Method
- Embolism
(prevention & control)
- Factor Xa Inhibitors
- Female
- Humans
- Intracranial Hemorrhages
(blood, chemically induced, epidemiology, physiopathology)
- Male
- Morpholines
(administration & dosage, adverse effects)
- Prospective Studies
- Rivaroxaban
- Stroke
(prevention & control)
- Thiophenes
(administration & dosage, adverse effects)
- Treatment Outcome
- Vitamin K
(antagonists & inhibitors)
- Warfarin
(administration & dosage, adverse effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|